8NE Stock Overview
A clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Lisata Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.64 |
| 52 Week High | US$3.34 |
| 52 Week Low | US$1.93 |
| Beta | 1.22 |
| 11 Month Change | 0.76% |
| 3 Month Change | 6.45% |
| 1 Year Change | 30.69% |
| 33 Year Change | -79.29% |
| 5 Year Change | -92.54% |
| Change since IPO | -99.61% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8NE | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 4.8% | -0.7% | -0.02% |
| 1Y | 30.7% | -17.2% | 8.2% |
Return vs Industry: 8NE exceeded the German Biotechs industry which returned -17.5% over the past year.
Return vs Market: 8NE exceeded the German Market which returned 7.4% over the past year.
Price Volatility
| 8NE volatility | |
|---|---|
| 8NE Average Weekly Movement | 9.0% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 8NE's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 8NE's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1980 | 25 | Dave Mazzo | www.lisata.com |
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Lisata Therapeutics, Inc. Fundamentals Summary
| 8NE fundamental statistics | |
|---|---|
| Market cap | €22.72m |
| Earnings (TTM) | -€19.92m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.2x
P/E RatioIs 8NE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8NE income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$20.74m |
| Earnings | -US$20.74m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.49 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 8NE perform over the long term?
See historical performance and comparison